Quantitative analysis of five tobacco-specific N-nitrosamines in urine by liquid chromatography-atmospheric pressure ionization tandem mass spectrometry

Biomedical Chromatography

Volumn 28, Issue 3, 2014, Pages 375-384

  Xia, Baoyun ^a   Xia, Yang ^a   Wong, Joshua ^a   Nicodemus, Keegan J ^a   Xu, Meng ^a   Lee, John ^a   Guillot, Tonya ^a   Li, James ^a  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

Liquid chromatography tandem mass spectrometry; Molecularly imprinted polymer (MIP); Smoker urine; Tobacco specific nitrosamines

Indexed keywords

ATMOSPHERIC IONIZATION; ATMOSPHERIC PRESSURE; BODY FLUIDS; HEALTH RISKS; IONIZATION OF LIQUIDS; KETONES; LIQUID CHROMATOGRAPHY; SMOKE; TOBACCO;

ATMOSPHERIC PRESSURE IONIZATION; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; MOLECULARLY IMPRINTED POLYMER; PYRIDYL; SMOKER URINE; TANDEM-MASS SPECTROMETRY; TOBACCO SPECIFIC NITROSAMINES; TOBACCO-SPECIFIC N-NITROSAMINES;

MASS SPECTROMETRY;

BETA GLUCURONIDASE; NITROSAMINE; TOBACCO SMOKE;

ACCURACY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; HEALTH HAZARD; HUMAN; HYDROLYSIS; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MEASUREMENT; PASSIVE SMOKING; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TOBACCO; URINALYSIS;

NICOTIANA TABACUM;

LIQUID-CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MOLECULARLY IMPRINTED POLYMER (MIP); SMOKER URINE; TOBACCO-SPECIFIC NITROSAMINES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDASE; HUMANS; HYDROLYSIS; LIMIT OF DETECTION; MOLECULAR IMPRINTING; NITROSAMINES; REPRODUCIBILITY OF RESULTS; SMOKING; TANDEM MASS SPECTROMETRY; TOBACCO;

EID: 84893728081     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3031     Document Type: Article

References (55)

1. Abraham TT, Lowe RH, Pirnay SO, Darwin WD and Huestis MA. Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. Journal of Analytical Toxicology 2007; 31(8): 477-485.
2. Agilent. 1200 Infinity Calculator, 2013. Available from: http://www.chem.agilent.com/en-US/products-services/Instruments-Systems/Liquid-Chromatography/Pages/1200infinity_cost_calculator.aspx (accessed 26 July 2013).
3. Andersen RA and Kemp TR. Accumulation of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone in alkaloid genotypes of burley tobacco during postharvest processing: comparisons with N′-nitrosonornicotine and probable nitrosamine precursors. Cancer Research 1985; 45(11 Pt 1): 5287-5293.
4. Annesley TM. Ion suppression in mass spectrometry. Clinical Chemistry 2003; 49(7): 1041-1044.
5. Benowitz NL, Dains KM, Dempsey D, Wilson M and Jacob P. Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine and Tobacco Research 2011; 13(9): 772-783.
6. Bhat SH, Gelhaus SL, Mesaros C, Vachani A and Blair IA. A new liquid chromatography/mass spectrometry method for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in urine. Rapid Communications in Mass Spectrometry 2011; 25(1): 115-121.
7. Carmella SG, Akerkar S and Hecht SS. Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers urine. Cancer Research 1993; 53(4): 721-724.
8. Carmella SG, Akerkar SA, Richie JP Jr and Hecht SS. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. Cancer Epidemiology, Biomarkers and Prevention 1995; 4(6): 635-642.
9. Carmella SG, Han S, Fristad A, Yang Y and Hecht SS. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human urine. Cancer Epidemiology, Biomarkers and Prevention 2003; 12: 1257-1261.
10. Carmella SG, Han S, Villalta PW and Hecht SS. Analysis of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' blood. Cancer Epidemiology, Biomarkers and Prevention 2005; 14: 2669-2672.
11. Carmella SG, Yoder A and Hecht SS. Combined analysis of r-1, t-2, 3, c-4-tetrahydroxy-1, 2, 3, 4-tetrahydrophenanthrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in smokers' plasma. Cancer Epidemiology, Biomarkers and Prevention 2006; 15(8): 1490-1494.
12. Caudill SP, Schleicher RL and Pirkle JL. Multi-rule quality control for the age-related eye disease study. Statistics in Medicine 2008; 27(20): 4094-4106.
13. CDC. Current cigarette smoking among adults - United States, 2011. Morbidity and Mortality Weekly Report, 2012; 61.
14. Duderstadt RE and Fischer SM. Effect of organic mobile phase composition on signal responses for selected polyalkene additive compounds by liquid chromatography-mass spectrometry. Journal of Chromatography, A 2008; 1193(1-2): 70-78.
15. Gao S, Zhang ZP and Karnes HT. Sensitivity enhancement in liquid chromatography/atmospheric pressure ionization mass spectrometry using derivatization and mobile phase additives. Journal of Chromatography 2005; 825(2): 98-110.
16. Hecht SS. Approaches to chemoprevention of lung cancer based on carcinogens in tobacco smoke. Environmental Health Perspectives 1997; 105: 955-963.
17. Hecht SS. Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chemical Research and Toxicology 1998; 11(6): 559-603.
18. Hecht SS. Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute 1999; 91(14): 1194-1210.
19. Hecht SS. Tobacco smoke carcinogens and breast cancer. Environment Molecules and Mutagenicity 2002a: 39(2-3): 119-126.
20. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 2002b: 23(6): 907-922.
21. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nature Reviews Cancer 2003; 3(10): 733-744.
22. Hecht SS and Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 1988; 9(6): 875-884.
23. Hecht SS, Carmella SG, Murphy SE, Riley WT, Le C, Luo X, Mooney M and Hatsukami DK. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiology, Biomarkers and Prevention 2007; 16(8): 1567-1572.
24. HHS. The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, 2004.
25. HHS. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, 2006.
26. HHS. How Tobacco Smoke Causes Disease: the Biology and Behavioral Basis for Smoking-attributable Disease: a Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA, 2010.
27. Hoffmann D, Raineri R, Hecht SS, Maronpot R and Wynder EL. A study of tobacco carcinogenesis. XIV. Effects of N′-nitrosonornicotine and N′-nitrosonanabasine in rats. Journal of the National Cancer Institute 1975; 55(4): 977-981.
28. Hoffmann D, Rivenson A, Amin S and Hecht SS. A study of tobacco carcinogenesis. 27. Dose-response study of the carcinogenicity of tobacco-specific N-nitrosamines in F344 rats. Journal of Cancer Research Clinics 1984; 108(1): 81-86.
29. Hoffmann D, Brunnemann KD, Prokopczyk B and Djordjevic MV. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity and relevance to humans. Journal of Toxicology and Environmental Health 1994; 41(1): 1-52.
30. IARC. Tobacco Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC: Lyon, Vol. 38, 1986.
31. IARC. Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC: Lyon, Vol. 83, 2004.
32. IARC. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42.IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC: Lyon, Vols 1-41, Supplement 7, 1987; 42.
33. IARC. Smokeless Tobacco and Some Tobacco-specific N-nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC: Lyon, Vol. 89, 2007.
34. Iniguez C, Ballester F, Amoros R, Murcia M, Plana A and Rebagliato M. Active and passive smoking during pregnancy and ultrasound measures of fetal growth in a cohort of pregnant women. Journal of Epidemiology and Community Health 2012; 66(6): 563-570.
35. IOM. Clearing the Smoke: The Science Base for Tobacco Harm Reduction. Institute of Medicine/National Academy Press: Washington, DC, 2001.
36. Kavvadias D, Scherer G, Cheung F, Errington G, Shepperd J and McEwan M. Determination of tobacco-specific N-nitrosamines in urine of smokers and non-smokers. Biomarkers 2009a: 14(8): 547-553.
37. Kavvadias D, Scherer G, Urban M, Cheung F, Errington G, Shepperd J, and McEwan M. Simultaneous determination of four tobacco-specific N-nitrosamines (TSNA) in human urine. Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2009b: 877(11-12): 1185-1192.
38. Khariwala SS, Hatsukami D and Hecht SS. Tobacco carcinogen metabolites and DNA adducts as biomarkers in head and neck cancer: potential screening tools and prognostic indicators. Head and Neck 2012; 34(3): 441-447.
39. Li C, Wen D, Zhang J, Chen Z, Cong W, Rao Z, and Liu H. Study of the metabolism on tobacco-specific N-nitrosamines in the rabbit by solid-phase extraction and liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry 2006; 386(7-8): 1985-1993.
40. Liang PS, Chen TY and Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: Systematic review and meta-analysis. International Journal of Cancer 2009; 124(10): 2406-2415.
41. Marklund M, Landberg R, Aman P and Kamal-Eldin A. Determination of alkylresorcinol metabolites in human urine by gas chromatography-mass spectrometry. Journal of Chromatography B 2010; 878(11-12): 888-894.
42. Richie JP, Jr, Carmella SG, Muscat JE, Scott DG, Akerkar SA and Hecht SS. Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers. Cancer Epidemiology, Biomarkers and Prevention 1997; 6(10): 783-790.
43. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V and on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens - part E: tobacco, areca nut, alcohol, coal smoke and salted fish. Lancet Oncology 2009; 10(11): 1033-1034.
44. Shah KA, Peoples MC, Halquist MS, Rutan SC and Karnes HT. Microfluidic direct injection method for analysis of urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) using molecularly imprinted polymers coupled on-line with LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2011; 54(2): 368-378.
45. Smith CJ, Perfetti TA, Garg R and Hansch C. IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. Food and Chemical Toxicology 2003; 41(6): 807-817.
46. Stepanov I and Hecht SS. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiology, Biomarkers and Prevention 2005; 14(4): 885-891.
47. Stepanov I, Upadhyaya P, Carmella SG, Feuer R, Jensen J, Hatsukami DK, and Hecht SS. Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiology, Biomarkers and Prevention 2008; 17(7): 1764-1773.
48. Sunyer J, Garcia-Esteban R, Castilla AM, Aurrekoetxea JJ, Iniguez C, Tardon A, Espada M, Lertxundi A, Chatzi L, Rebagliato M, Kogevinas M and INMA project. Exposure to second-hand smoke and reproductive outcomes depending on maternal asthma. European Respiratory Journal 2012; 40(2): 371-376.
49. Tomlinson AJ and Chicz RM. Microcapillary liquid chromatography/tandem mass spectrometry using alkaline pH mobile phases and positive ion detection. Rapid Communications in Mass Spectrometry 2003; 17(9): 909-916.
50. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, Sitas F, Smith J, Stayner L, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze D, Peto R and Doll R. Tobacco and cancer: recent epidemiological evidence. Journal of the National Cancer Institute 2004; 96(2): 99-106.
51. Xia Y and Bernert JT. Stability of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine samples stored at various temperatures. Journal of Analytical Toxicology 2010; 34(7): 411-415.
52. Xia Y, McGuffey JE, Bhattacharyya S, Sellergren B, Yilmaz E, Wang LQ, and Bernert JT. Analysis of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine by extraction on a molecularly imprinted polymer column and liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Analytical Chemistry 2005; 77(23): 7639-7645.
53. Xia Y, Bernert JT, Jain RB, Ashley DL and Pirkle JL. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in smokers in the United States: NHANES 2007-2008. Biomarkers 2011; 16(2): 112-119.
54. Yuan JM, Knezevich AD, Wang RW, Gao YT, Hecht SS and Stepanov I. Urinary levels of the tobacco-specific carcinogen N′-nitrosonornicotine and its glucuronide are strongly associated with esophageal cancer risk in smokers. Carcinogenesis 2011; 32(9): 1366-1371.
55. Zagierski M, Szlagatys-Sidorkiewicz A, Jankowska A, Krzykowski G, Korzon M and Kaminska B. Maternal smoking decreases antioxidative status of human breast milk. Journal of Perinatology 2012; 32(8): 593-597.